• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Will a New Shingles Vaccine Provide the Boost GlaxoSmithKline Desires?

    Chelsea Pratt
    Sep. 15, 2016 04:11AM PST
    Biotech Investing
    Biotech Investing

    Shingrix, an experimental vaccine from GlaxoSmithKline, has produced promising data in its latest clinical trial. Researchers have found that the shingles vaccine candidate protects 90 percent of people aged 70 or older from developing the painful disease and offers at least four years of immunity.

    Shingrix, an experimental vaccine from GlaxoSmithKline (NYSE:GSK), has produced promising data in its latest clinical trial. Researchers have found that the shingles vaccine candidate protects 90 percent of people aged 70 or older from developing the painful disease and offers at least four years of immunity.
    The trial involved some 14,800 adults over 70, who were administered either two doses of the vaccine or two doses of a placebo. A previous clinical trial, focused on people over 50, found the vaccine to be 97 percent effective.
    Those numbers are particularly impressive when compared to the efficacy of the shingles vaccine currently on the market: Zostavax, developed by Merck (NYSE:MRK), has a 50 percent success rate in preventing shingles.
    It’s good news for GlaxoSmithKline, which has lost patent protection for several key drugs in recent years, including Advair, Valtrex, Lovaza and Seretide. The arrival of generic competitors has hit the company hard, although the success of their HIV drug line seemed to somewhat offset that lost revenue. Shingrix may provide a similar boost.
    After all, the market for such a vaccine is huge: anyone who has had chickenpox is vulnerable—and that’s virtually anyone over 40 in the United States. In fact, the Center for Disease Control estimates that one in three Americans will develop shingles in their lifetime. Although the disease rarely leads to death, the rash is very painful, often recurring and can cause excruciating complications like postherpatic neuralgia.


    Negative side effects of Shingrix, which include fatigue and muscle pain, so far appear minimal. HealthDay News reported some concern that adjuvant, a key component of the vaccine, may negatively affect the immune system of people with certain genetic markers. However, GlaxoSmithKline still expects to apply for FDA approval before the end of the year.

    Don’t forget to follow us @INN_LifeScience for real-time news updates.
    Securities Disclosure: I, Chelsea Pratt, hold no direct investment interest in any company mentioned in this article.
    chelsea prattfda approvalhealth companies
    The Conversation (0)

    Go Deeper

    AI Powered
    Pfizer Reports First-Quarter 2023 Results

    Pfizer Reports First-Quarter 2023 Results

    Scientist with petri dish.

    Pharma Market Forecast: Top Trends for Pharma in 2025

    Latest News

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×